Tevogen Bio Holdings Inc (NASDAQ:TVGN) does about 1.86M shares in volume on a normal day but saw 527308 shares change hands in the recent trading day. The company now has a market cap of 180.14M USD. Its current market price is $0.98, marking a decrease of -3.96% compared to the previous close of $1.02. The 52 week high reached by this stock is $3.09 whilst the lowest price level in 52 weeks is $0.26.
Tevogen Bio Holdings Inc (TVGN) has a 20-day trading average at $1.0860 and the current price is -68.30% off the 52-week high compared with 283.26% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.2195 and its 200-day simple moving average is $1.0624. If we look at the stock’s price movements over the week, volatility stands at 10.02%, which decreases to 9.55% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 40.81 to suggest the stock is neutral.
The consensus objective for the share price is $10.00, suggesting that the stock has a potential upside of 90.2% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 04, 2025 when D. Boral Capital initiated the stock to “Buy” and issued a price target of $10.
The current price level is -9.80%, -19.67%, and -7.79% away from its SMA20, SMA50, and SMA200 respectively, with the TVGN price moving above the 50-day SMA on current market day. Tevogen Bio Holdings Inc (TVGN) stock is down -2.04% over the week and -14.07% over the past month. Its price is -4.89% year-to-date and -58.49% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 90.2 percent from here.
Outstanding shares total 177.99M with insiders holding 84.63% of the shares and institutional holders owning 1.39% of the company’s common stock. The company has a return on equity of -124.74%. The beta has a value of -0.68.
